Conyers advises Hony Capital Fund V and New Good Management on privatisation of Simcere

Conyers Dill & Pearman has advised Hony Capital Fund V and New Good Management on the $495m (£300m) privatisation of Simcere Pharmaceutical Group from the New York Stock Exchange (NYSE) by way of merger.

Simcere is a pharmaceutical company specialising in the development, manufacture and marketing of branded and proprietary pharmaceuticals in China.

Conyers co-chair David Lamb and associate Angie Chu, both based in Conyers’ Hong Kong office, acted in this matter. They worked alongside Cleary Gottlieb Steen & Hamilton and Shearman & Sterling.